Physician s Desk Reference

Physician s Desk Reference, 48th ed.. Medical Economics Data Production, Montvale, N.J., 1994, p. 2414. 

A. B. Miller, The Physician s Desk Reference, 25th ed., Litton Pubhcations, OradeU, N.J., 1971. 

Physician s Desk Reference for Ophthalmology, 28th Ed., 2000, Section 9. 

Physician s Desk Reference. PDR for Herbal Medicines. NJ Medical Economics Company, 1999. 

Even unifying information about a very specific field such as the pharmacology of discrete drugs is a monumental task. The primary reason for this difficulty is the disparity of purpose between various information sources. Consider how different the purposes are ofWDI (World Drug Index) [20], PDR (Physician s Desk Reference) [21], MSDS (Material Safety Data Sheets) [22] and REG (Chemical Abstracts Registry) [23], each of which has a different natural data model. 

PDR (Physician s Desk Reference), http //www.pdr.net/pdrnet/librarian... 

This appendix describes the patent listing and litigation history for each of the eight drug products listed in Tables 4-2 and 4-3 that obtained multiple 30-month stays. The relationship of the litigated patents creating the stays to the approved drug product (as detailed in the Physician s Desk Reference) is also described. 

The Physician s Desk Reference is a comprehensive book that provides doctors with information about the uses and side effects of all FDA-approved medications. Often the entries for medications are based on the documents provided by drug companies on their own products. 

Although tricyclics continue to be used today to treat childhood depression (Zito et ah, 2000), the use in children with ADHD has decreased, most likely because of its association with the sudden deaths of five children (Biederman, 1991). Furthermore, the Physician s Desk Reference (PDR) warns that MPH may inhibit the metabolism of tricyclics, but no such warning exists for DEX or (AMP). Due to the concern that children on this combination of medications are prone to develop more side effects, it is not a recommended form of treatment. Instead, MPH combined with a selective serotonin reuptake inhibitor is preferable for treating a child with ADHD and comorbid depression. 

Physician s Desk Reference 55th ed.. (2001), Montvale, NJ Medical Economics Data. 

Similar to the BZD anxiolytics, BZD hypnotics can be classified by their elimination half-life into those that are long-acting, those that are intermediate-acting, and those that are short-acting (Table 12-5). The Physician s Desk Reference (PDR) (93) aptly calls attention to the postulated relationship... 

This situation is true for virtually all areas of pediatric clinical pharmacology. Of prescription drugs marketed in the United States, 80% are not approved by the FDA for use in children (29). The situation has changed little in the past 20 years. In 1973, 78% of the 2,000 prescription medications listed in the Physician s Desk Reference had labeling with proscription against their use in children. The same was true in 1992. Of the 53 new drugs approved in 1996, 37 were approved for the treatment of conditions that occur in children as well as adults, yet 30 of these drugs were approved only for adults. 

Physician s Desk Reference, 60th ed., Thomson Publishing, Montvale, NJ, 2006. 

Several other types of drugs are administered for specific purposes in controlling GI function. These other drugs are introduced here only to alert the reader to their existence. For a more detailed description of the use of any of these agents, one of the drug indexes such as the Physician s Desk Reference (PDR) should be consulted. 

According to the Physician s Desk Reference (PDR) for Nutritional Supplements, there are no known adverse interactions between creatine monohydrate supplements and prescription drugs, herbs, and/or other dietary supplements. However, the effects of creatine may be decreased or altered by the use of other drugs or supplements, so anyone considering taking the supplement should consult a physician first. 

---